☆ 4.5 Letter

Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma

BLOOD CANCER JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Article Hematology

Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database

Pierre-Marie Morice et al.

Summary: The study found that PARP inhibitors increase the risk of myelodysplastic syndrome and acute myeloid leukaemia compared to placebo treatment. These delayed and often lethal adverse events should be further studied to improve clinical understanding, particularly in the front-line maintenance setting.

LANCET HAEMATOLOGY (2021)

Add to Collection

Article Hematology

Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy

Peter G. Miller et al.

Summary: CHIP, a state in which mutations in hematopoietic cells give rise to a clonal population of cells, is common in patients receiving CAR T-cell therapy but does not impact progression-free or overall survival, especially in patients younger than 60 years old. Although it can influence response rates and cytokine release syndrome severity, it should not be a factor in determining eligibility for this potentially life-prolonging treatment.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells

Ana Cordeiro et al.

BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)

Add to Collection

Review Oncology

Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy A Systematic Review

Mohamad Bassam Sonbol et al.

JAMA ONCOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

Michael Wang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Genetics & Heredity

Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia

Alexandra Higgins et al.

GENES (2020)

Add to Collection

Article Hematology

MDS AS A CAUSE FOR PROLONGED HEMATOLOGIC TOXICITY AFTER TREATMENT WITH CD19 TARGETED CAR-T CELL THERAPY IN PATIENTS WITH RELAPSED REFRACTORY LYMPHOMA

G.P. Shouse et al.

HEMATOLOGICAL ONCOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma

Tomas Radivoyevitch et al.

LEUKEMIA RESEARCH (2018)

Add to Collection

Review Medicine, General & Internal

Chimeric Antigen Receptor Therapy

Carl H. June et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Oncology

Therapy-related myeloid neoplasms: when genetics and environment collide

Megan E. McNerney et al.

NATURE REVIEWS CANCER (2017)

Add to Collection

Article Oncology

Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients

JO Armitage et al.

JOURNAL OF CLINICAL ONCOLOGY (2003)

Add to Collection

Article Oncology

Therapy-related myelodysplasia and secondary acute myelogenous leukemia after high-dose therapy with autologous hematopoietic progenitor-cell support for lymphoid malignancies

INM Micallef et al.

JOURNAL OF CLINICAL ONCOLOGY (2000)

Add to Collection

© Peeref 2019-2024. All rights reserved.